<collection>
    <source>BioC-API</source>
    <date>20240515</date>
    <key>collection.key</key>
    <document>
        <id>7933980</id>
        <infon key="license">CC BY</infon>
        <passage>
            <infon key="article-id_doi">10.1212/NXG.0000000000000149</infon>
            <infon key="article-id_pmc">5413961</infon>
            <infon key="article-id_pmid">28508084</infon>
            <infon key="article-id_publisher-id">NG2016004481</infon>
            <infon key="elocation-id">e149</infon>
            <infon key="issue">3</infon>
            <infon key="license">This is an open access article distributed under the terms of the
                Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use,
                distribution, and reproduction in any medium, provided the original work is properly
                cited.</infon>
            <infon key="name_0">surname:Bugiardini;given-names:Enrico</infon>
            <infon key="name_1">surname:Poole;given-names:Olivia V.</infon>
            <infon key="name_10">surname:Plant;given-names:Gordon T.</infon>
            <infon key="name_11">surname:Poulton;given-names:Joanna</infon>
            <infon key="name_12">surname:Zeviani;given-names:Massimo</infon>
            <infon key="name_13">surname:Ghezzi;given-names:Daniele</infon>
            <infon key="name_14">surname:Taylor;given-names:John</infon>
            <infon key="name_15">surname:Smith;given-names:Conrad</infon>
            <infon key="name_16">surname:Fratter;given-names:Carl</infon>
            <infon key="name_17">surname:Kanikannan;given-names:Meena A.</infon>
            <infon key="name_18">surname:Paramasivam;given-names:Arumugam</infon>
            <infon key="name_19">surname:Thangaraj;given-names:Kumarasamy</infon>
            <infon key="name_2">surname:Manole;given-names:Andreea</infon>
            <infon key="name_20">surname:Spinazzola;given-names:Antonella</infon>
            <infon key="name_21">surname:Holt;given-names:Ian J.</infon>
            <infon key="name_22">surname:Houlden;given-names:Henry</infon>
            <infon key="name_23">surname:Hanna;given-names:Michael G.</infon>
            <infon key="name_24">surname:Pitceathly;given-names:Robert D.S.</infon>
            <infon key="name_3">surname:Pittman;given-names:Alan M.</infon>
            <infon key="name_4">surname:Horga;given-names:Alejandro</infon>
            <infon key="name_5">surname:Hargreaves;given-names:Iain</infon>
            <infon key="name_6">surname:Woodward;given-names:Cathy E.</infon>
            <infon key="name_7">surname:Sweeney;given-names:Mary G.</infon>
            <infon key="name_8">surname:Holton;given-names:Janice L.</infon>
            <infon key="name_9">surname:Taanman;given-names:Jan-Willem</infon>
            <infon key="section_type">TITLE</infon>
            <infon key="type">front</infon>
            <infon key="volume">3</infon>
            <infon key="year">2017</infon>
            <offset>0</offset>
            <text>Clinicopathologic and molecular spectrum of RNASEH1-related mitochondrial disease</text>
        </passage>
        <passage>
            <infon key="section_type">ABSTRACT</infon>
            <infon key="type">abstract_title_1</infon>
            <offset>82</offset>
            <text>Objective:</text>
        </passage>
        <passage>
            <infon key="section_type">ABSTRACT</infon>
            <infon key="type">abstract</infon>
            <offset>93</offset>
            <text>Pathologic ribonuclease H1 (RNase H1) causes aberrant mitochondrial DNA (mtDNA)
                segregation and is associated with multiple mtDNA deletions. We aimed to determine
                the prevalence of RNase H1 gene (RNASEH1) mutations among patients with
                mitochondrial disease and establish clinically meaningful genotype-phenotype
                correlations.</text>
        </passage>
        <passage>
            <infon key="section_type">ABSTRACT</infon>
            <infon key="type">abstract_title_1</infon>
            <offset>419</offset>
            <text>Methods:</text>
        </passage>
        <passage>
            <infon key="section_type">ABSTRACT</infon>
            <infon key="type">abstract</infon>
            <offset>428</offset>
            <text>RNASEH1 was analyzed in patients with (1) multiple deletions/depletion of muscle
                mtDNA and (2) mendelian progressive external ophthalmoplegia (PEO) with
                neuropathologic evidence of mitochondrial dysfunction, but no detectable multiple
                deletions/depletion of muscle mtDNA. Clinicopathologic and molecular evaluation of
                the newly identified and previously reported patients harboring RNASEH1 mutations
                was subsequently undertaken.</text>
        </passage>
        <passage>
            <infon key="section_type">ABSTRACT</infon>
            <infon key="type">abstract_title_1</infon>
            <offset>857</offset>
            <text>Results:</text>
        </passage>
        <passage>
            <infon key="section_type">ABSTRACT</infon>
            <infon key="type">abstract</infon>
            <offset>866</offset>
            <text>Pathogenic c.424G>A p.Val142Ile RNASEH1 mutations were detected in 3 pedigrees
                among the 74 probands screened. Given that all 3 families had Indian ancestry,
                RNASEH1 genetic analysis was undertaken in 50 additional Indian probands with
                variable clinical presentations associated with multiple mtDNA deletions, but no
                further RNASEH1 mutations were confirmed. RNASEH1-related mitochondrial disease was
                characterized by PEO (100%), cerebellar ataxia (57%), and dysphagia (50%). The
                ataxia neuropathy spectrum phenotype was observed in 1 patient. Although the
                c.424G>A p.Val142Ile mutation underpins all reported RNASEH1-related mitochondrial
                disease, haplotype analysis suggested an independent origin, rather than a founder
                event, for the variant in our families.</text>
        </passage>
        <passage>
            <infon key="section_type">ABSTRACT</infon>
            <infon key="type">abstract_title_1</infon>
            <offset>1629</offset>
            <text>Conclusions:</text>
        </passage>
        <passage>
            <infon key="section_type">ABSTRACT</infon>
            <infon key="type">abstract</infon>
            <offset>1642</offset>
            <text>In our cohort, RNASEH1 mutations represent the fourth most common cause of adult
                mendelian PEO associated with multiple mtDNA deletions, following mutations in POLG,
                RRM2B, and TWNK. RNASEH1 genetic analysis should also be considered in all patients
                with POLG-negative ataxia neuropathy spectrum. The pathophysiologic mechanisms by
                which the c.424G>A p.Val142Ile mutation impairs human RNase H1 warrant further
                investigation.</text>
        </passage>
        <passage>
            <infon key="section_type">INTRO</infon>
            <infon key="type">paragraph</infon>
            <offset>2068</offset>
            <text>Mitochondrial diseases are commonly inherited disorders caused by mutations in
                nuclear and mitochondrial DNA (mtDNA). Dysfunction in a subset of nuclear genes
                involved with mtDNA maintenance results in the secondary accumulation of multiple
                deletions and/or depletion of muscle mtDNA. The clinical spectrum of this group of
                disorders is broad, ranging from severe infantile hepatocerebral syndromes to
                benign, late-onset progressive external ophthalmoplegia (PEO). Mutations in the
                mtDNA maintenance gene RNASEH1, encoding ribonuclease H1 (RNase H1), have recently
                been linked to adult mitochondrial disease presenting with CNS and neuromuscular
                involvement. RNase H1 degrades RNA hybridized to DNA, and knockout mice suffer
                embryonic lethality owing to mtDNA depletion, attributable to persistent mtDNA
                RNA/DNA hybrids. However, humans with RNASEH1 mutations develop a relatively mild
                clinical syndrome, comprising adult-onset PEO associated with multiple mtDNA
                deletions secondary to the impaired physical segregation of mtDNA molecules. The
                prevalence and clinical spectrum of RNASEH1-related mitochondrial disease is
                currently unknown.</text>
        </passage>
        <passage>
            <infon key="section_type">INTRO</infon>
            <infon key="type">paragraph</infon>
            <offset>3208</offset>
            <text>We screened 74 unrelated probands with genetically undetermined mitochondrial
                disease for RNASEH1 mutations. The previously reported pathogenic missense
                transition c.424G>A p.Val142Ile was detected in 3 families with Indian ancestry:
                homozygous mutations were confirmed in 2 pedigrees and compound heterozygous
                mutations in combination with a novel c.442T>C p.Cys148Arg variant in a third.
                Detailed clinicopathologic and molecular profiling of these newly identified
                families harboring RNASEH1 mutations, and evaluation of all previously reported
                cases, was subsequently undertaken to determine the phenotypic spectrum of
                RNASEH1-mediated mitochondrial disease and establish clinically meaningful
                genotype-phenotype correlations. Finally, the ancestral origins of the "common"
                RNASEH1 c.424G>A p.Val142Ile mutation were investigated.</text>
        </passage>
        <passage>
            <infon key="section_type">METHODS</infon>
            <infon key="type">title_1</infon>
            <offset>4046</offset>
            <text>METHODS</text>
        </passage>
        <passage>
            <infon key="section_type">METHODS</infon>
            <infon key="type">title_2</infon>
            <offset>4054</offset>
            <text>Participants.</text>
        </passage>
        <passage>
            <infon key="section_type">METHODS</infon>
            <infon key="type">paragraph</infon>
            <offset>4068</offset>
            <text>Patients referred to the London and Oxford NHS England nationally commissioned
                service for mitochondrial diseases were recruited to the study according to the
                following criteria: (1) confirmed multiple deletions/depletion of muscle mtDNA and
                (2) mendelian PEO with pathologic evidence of mitochondrial dysfunction, including
                ragged red fibers (RRFs) and/or cytochrome c oxidase (COX)-negative muscle fibers,
                without detectable multiple deletions or depletion of muscle mtDNA. RNASEH1 genetic
                analysis was also undertaken in a cohort of Indian patients with evidence of
                multiple mtDNA deletions detectable in muscle.</text>
        </passage>
        <passage>
            <infon key="section_type">METHODS</infon>
            <infon key="type">title_2</infon>
            <offset>4684</offset>
            <text>Genetic studies.</text>
        </passage>
        <passage>
            <infon key="section_type">METHODS</infon>
            <infon key="type">paragraph</infon>
            <offset>4701</offset>
            <text>Whole-exome and Sanger sequencing was used to analyze the 8 coding exons and
                intron-exon boundaries of RNASEH1 (primer sequences available on request).</text>
        </passage>
        <passage>
            <infon key="section_type">METHODS</infon>
            <infon key="type">title_2</infon>
            <offset>4853</offset>
            <text>Clinicopathologic and molecular evaluation of patients.</text>
        </passage>
        <passage>
            <infon key="section_type">METHODS</infon>
            <infon key="type">paragraph</infon>
            <offset>4909</offset>
            <text>Patients harboring RNASEH1 mutations were assessed clinically by the authors.
                Medical records and muscle tissue histopathologic and electron microscopy findings
                were reviewed. Real-time quantitative PCR of DNA extracted from muscle was
                undertaken in all patients harboring RNASEH1 mutations and multiple mtDNA deletions
                to exclude coexisting mtDNA depletion. Previously published RNASEH1 variants
                (pathogenic and of unknown significance) were evaluated and clinicopathologic and
                genotypic data extracted and combined with the London-Oxford cohort to accurately
                define the clinical genetic spectrum of all known RNASEH1-mediated mitochondrial
                disease.</text>
        </passage>
        <passage>
            <infon key="section_type">METHODS</infon>
            <infon key="type">title_2</infon>
            <offset>5560</offset>
            <text>Principal component analysis, identity by descent, and haplotyping.</text>
        </passage>
        <passage>
            <infon key="section_type">METHODS</infon>
            <infon key="type">paragraph</infon>
            <offset>5628</offset>
            <text>Principal component analysis (PCA), using GCTA software (version 1.26.0), was
                performed relative to the HapMap project populations (CEU, JPT, and YRI) to study
                the geographical origin of 2 Indian families where exome-sequencing data were
                available (families A and B). Identity by descent (IBD) analysis was utilized in
                plink software (v1.90 b1g) to explore the possibility of a common lineage for the
                pedigrees. Haplotyping was adopted to investigate the possibility of a common origin
                for the c.424G>A p.Val142Ile mutation. Six single nucleotide variants extracted from
                available exome data were used to construct haplotypes around the mutation site, and
                Sanger sequencing of the variants in affected individuals from the London-Oxford
                cohort and in 2 previously reported families was undertaken. Haplotypes were phased
                around homozygous variant sites only, given parental samples were unavailable.</text>
        </passage>
        <passage>
            <infon key="section_type">METHODS</infon>
            <infon key="type">title_2</infon>
            <offset>6528</offset>
            <text>Standard protocol approvals, registrations, and patient consents.</text>
        </passage>
        <passage>
            <infon key="section_type">METHODS</infon>
            <infon key="type">paragraph</infon>
            <offset>6594</offset>
            <text>The study was approved and performed under the ethical guidelines issued by our
                institutions for clinical studies, with written informed consent obtained from all
                participants for genetic studies.</text>
        </passage>
        <passage>
            <infon key="section_type">RESULTS</infon>
            <infon key="type">title_1</infon>
            <offset>6791</offset>
            <text>RESULTS</text>
        </passage>
        <passage>
            <infon key="section_type">RESULTS</infon>
            <infon key="type">title_2</infon>
            <offset>6799</offset>
            <text>RNASEH1 sequence data analysis.</text>
        </passage>
        <passage>
            <infon key="section_type">RESULTS</infon>
            <infon key="type">paragraph</infon>
            <offset>6831</offset>
            <text>Seventy-four unrelated probands were recruited from the London and Oxford NHS
                England nationally commissioned service for mitochondrial diseases and categorized
                as follows: multiple deletions (n = 33) and depletion (n = 21) of muscle mtDNA and
                mendelian PEO with neuropathologic evidence of mitochondrial dysfunction, but no
                detectable multiple deletions/depletion of muscle mtDNA (n = 20). Homozygous RNASEH1
                c.424G>A p.Val142Ile mutations were identified in 2, apparently unrelated,
                nonconsanguineous families (family A: A-III.8, A-III.9, A-III.10, and A-III.11; and
                family B: B-II.1 and B-II.8), and a third singleton case (family C: C-II.1) was
                compound heterozygous with the novel missense mutation c.442T>C p.Cys148Arg (figure
                1A). Parental segregation was confirmed. All 3 families had Indian ancestry.
                Affected individuals harbored multiple deletions of muscle mtDNA. Fifty additional
                unrelated Indian probands with multiple deletions of muscle mtDNA deletions were
                screened for RNASEH1 mutations (see table e-1 at Neurology.org/ng, for
                clinicopathologic spectrum), but no known or novel RNASEH1 variants were detected.</text>
        </passage>
        <passage>
            <infon key="file">NG2016004481FF1.jpg</infon>
            <infon key="id">F1</infon>
            <infon key="section_type">FIG</infon>
            <infon key="type">fig_title_caption</infon>
            <offset>7959</offset>
            <text>Pedigrees and histopathologic findings of patients harboring RNASEH1 c.424G>A
                p.Val142Ile mutations</text>
        </passage>
        <passage>
            <infon key="file">NG2016004481FF1.jpg</infon>
            <infon key="id">F1</infon>
            <infon key="section_type">FIG</infon>
            <infon key="type">fig_caption</infon>
            <offset>8059</offset>
            <text>(A) Pedigrees of families harboring RNASEH1 mutations. Filled blue symbols
                represent affected individuals. Arrows indicate probands. Long range PCR (LPCR) and
                Southern blot (SB) demonstrate multiple deletions of muscle mitochondrial DNA
                (B-II.8) in patient (P) when compared with control muscle (C). (B) Muscle biopsy
                histology (A-III.8) demonstrating ragged red fibers (modified Gomori trichrome, GT),
                ragged blue fibers (succinate dehydrogenase, SDH), and several muscle fibers
                deficient in cytochrome c oxidase (COX), arrows. Scale bar represents 50 mum in GT
                and 200 mum in SDH and COX. (C) Ultrastructural examination (A-III.8) showing
                increased numbers of mitochondria, many of which are structurally abnormal,
                including the presence of paracrystalline inclusions, arrows. Scale bar represents 1
                mum.</text>
        </passage>
        <passage>
            <infon key="section_type">RESULTS</infon>
            <infon key="type">title_2</infon>
            <offset>8866</offset>
            <text>Clinicopathologic and molecular features in RNASEH1 mutations.</text>
        </passage>
        <passage>
            <infon key="section_type">RESULTS</infon>
            <infon key="type">paragraph</infon>
            <offset>8929</offset>
            <text>Mean age of symptom onset in the London-Oxford cohort was 29 years (range, 13-36
                years). All patients presented with either ptosis or imbalance. The clinical
                phenotype was characterized by PEO, proximal muscle weakness, and cerebellar ataxia.
                One patient had a sensory ataxic neuropathy, with nerve conduction studies (NCS) and
                EMG indicative of a nonlength-dependent, predominantly sensory, axonal neuropathy.
                Brain MRI demonstrated moderate generalized parenchymal volume loss (n = 2).
                Histopathologic examination of muscle revealed RRFs and COX-negative fibers in all
                cases examined, while ultrastructural examination showed increased and abnormal
                mitochondria, many with paracrystalline inclusions (figure 1, B and C). There was no
                evidence of a coexisting reduction in muscle mtDNA copy number (B-II.8 and C-II.1).</text>
        </passage>
        <passage>
            <infon key="section_type">RESULTS</infon>
            <infon key="type">paragraph</infon>
            <offset>9751</offset>
            <text>Three families (6 affected individuals) with confirmed RNASEH1 mutations have
                previously been reported. An additional case was identified from variants of unknown
                significance published in exome-sequencing studies. These data were combined with
                the London-Oxford cohort and confirmed that PEO was a universal feature in patients
                with RNASEH1-related mitochondrial disease and that a substantial proportion of
                patients (57%) exhibited cerebellar dysfunction. Additional clinical features
                (summarized in table 1) included dysphagia (50%), proximal muscle weakness (36%),
                peripheral neuropathy (36%), and pyramidal signs (14%). NCS and EMG were consistent
                with involvement of motor and/or sensory nerve fibers with demyelinating, axonal, or
                ganglionic features. RRFs and/or COX-deficient fibers and multiple mtDNA deletions
                were reported in all cases when muscle tissue was available.</text>
        </passage>
        <passage>
            <infon key="file" />
            <infon key="id">T1</infon>
            <infon key="section_type">TABLE</infon>
            <infon key="type">table_caption</infon>
            <offset>10633</offset>
            <text>Clinicopathologic, biochemical, and genetic features of newly reported and
                previously published adults with RNASEH1-related mitochondrial disease</text>
        </passage>
        <passage>
            <infon key="section_type">RESULTS</infon>
            <infon key="type">paragraph</infon>
            <offset>10779</offset>
            <text>The c.424G>A p.Val142Ile mutation was detected in all 7 families (both newly
                reported and previously published). Three were homozygous and 4 were compound
                heterozygous with the following mutations: c.442T>C p.Cys148Arg (n = 2), c.469C>T
                p.Arg157*, and c.554C>T p.Ala185Val.</text>
        </passage>
        <passage>
            <infon key="section_type">RESULTS</infon>
            <infon key="type">title_2</infon>
            <offset>11053</offset>
            <text>PCA, IBD, and haplotyping.</text>
        </passage>
        <passage>
            <infon key="section_type">RESULTS</infon>
            <infon key="type">paragraph</infon>
            <offset>11080</offset>
            <text>PCA revealed that families A and B clustered to the same ethnic group (figure 2A,
                top panel), while IBD analysis implied a distant relationship to approximately
                second cousins (mean PI_HAT 0.049 +- 0.013). Haplotyping of families A and B
                suggested one shared founder haplotype of 3.67 Mb which was also present in family
                C. However, given that the c.424G>A p.Val142Ile variant was heterozygous, it was not
                possible to decipher whether this represented a population-specific or an ancestral
                mutation (figure 2A, bottom panel). Analysis of the same haplotype marker set in 2
                previously reported pedigrees with European ancestry (S1 and S3) revealed a
                different haplotype at single nucleotide polymorphism rs10186193, 74 base pairs away
                from the c.424G>A p.Val142Ile mutation. These data are consistent with an
                independent origin for the c.424G>A p.Val142Ile mutation in the patients analyzed.</text>
        </passage>
        <passage>
            <infon key="file">NG2016004481FF2.jpg</infon>
            <infon key="id">F2</infon>
            <infon key="section_type">FIG</infon>
            <infon key="type">fig_title_caption</infon>
            <offset>11971</offset>
            <text>Principal component and haplotype analysis of families harboring c.424G>A
                p.Val142Ile variant and schematic illustrating the newly identified and previously
                reported RNASEH1 mutations to date</text>
        </passage>
        <passage>
            <infon key="file">NG2016004481FF2.jpg</infon>
            <infon key="id">F2</infon>
            <infon key="section_type">FIG</infon>
            <infon key="type">fig_caption</infon>
            <offset>12163</offset>
            <text>(A) Principal component analysis (top panel). X-axis represents component 1;
                Y-axis represents component 2. Families A and B cluster to the same ethnic group.
                Haplotype analysis of individuals harboring the RNASEH1 mutation c.424G>A
                p.Val142Ile (bottom panel). "1" indicates the presence of the marker, "0" indicates
                the absence of the marker, and "0/1" is used when haplotype could not be phased.
                Haplotypes reported are for A-III.8, B-II.8, C-II.1, S-1, and S-3. Green = c.424G>A
                mutation; gray = markers differing from reference haplotype. Families A and B shared
                a haplotype of at least 3.57 Mb. However, 2 additional haplotypes were different,
                suggesting distant recombination events or that the haplotypes arose independently.
                (B) The RNASEH1 gene has 8 exons encoding 4 protein domains as follows:
                mitochondrial targeting sequencing domain (M), hybrid-binding domain (HBD),
                connection domain (CD), and ribonuclease H domain (H-domain). The latter conducts
                all catalytic activity. Both herein newly identified and previously reported
                mutations are illustrated in the schematic. To date, all affected individuals harbor
                the "common" c.424G>A p.Val142Ile mutation either in homozygous or heterozygous
                states. Brackets = number of families with each mutation. Red = newly reported
                variant.</text>
        </passage>
        <passage>
            <infon key="section_type">DISCUSS</infon>
            <infon key="type">title_1</infon>
            <offset>13472</offset>
            <text>DISCUSSION</text>
        </passage>
        <passage>
            <infon key="section_type">DISCUSS</infon>
            <infon key="type">paragraph</infon>
            <offset>13483</offset>
            <text>Based on data obtained from patients referred to the London and Oxford NHS England
                nationally commissioned service for mitochondrial diseases, RNASEH1 mutations
                represent the fourth most common cause of mendelian PEO associated with multiple
                mtDNA deletions in adults (2.7%, 3/109), following mutations in POLG (24.7%,
                27/109), RRM2B (16.5%, 18/109), and TWNK (also known as C10orf2, PEO1, or Twinkle,
                16.5%, 18/109). Additional, but less frequent, causes of adult mendelian PEO
                associated with multiple mtDNA deletions in our cohort include SLC25A4 (ANT1), OPA1,
                MFN2, TYMP, TK2, and SPG7 (1/109, 0.9%), while AFG3L2, DNA2, MGME1, POLG2, DGUOK,
                and MPV17 were not detected.</text>
        </passage>
        <passage>
            <infon key="section_type">DISCUSS</infon>
            <infon key="type">paragraph</infon>
            <offset>14158</offset>
            <text>Two families, in whom affected individuals harbored multiple mtDNA deletions, were
                homozygous for the previously reported c.424G>A p.Val142Ile mutation, thus
                confirming its pathogenicity and the importance of RNase H1 in mtDNA maintenance. A
                third proband was compound heterozygous with a novel missense mutation c.442T>C
                p.Cys148Arg in a highly conserved region of the enzyme, resulting in a hydrophobic
                amino acid being replaced by a positively charged residue within the RNase H1 active
                site. This mutation was previously reported as a variant of unknown significance in
                a patient with PEO harboring the POLG2 variant c.1105A>G p.Arg369Gly, which was
                favored as being causative. However, a minor allele frequency of 0.003 suggests that
                the POLG2 variant c.1105A>G p.Arg369Gly is a benign polymorphism and unlikely to be
                deleterious. Furthermore, the similarity in clinical phenotypes and association with
                identical mutations in our cohort supports the pathogenic basis of RNASEH1 c.442T>C
                p.Cys148Arg when a second mutant allele is present.</text>
        </passage>
        <passage>
            <infon key="section_type">DISCUSS</infon>
            <infon key="type">paragraph</infon>
            <offset>15202</offset>
            <text>Clinically, RNASEH1-linked mitochondrial disease is relatively homogenous,
                comprising PEO, cerebellar ataxia, dysphagia, and proximal muscle weakness. This
                could reflect similar structural and functional consequences of the reported RNASEH1
                mutations. Indeed, all patients are homozygous or heterozygous for c.424G>A
                p.Val142Ile, and remaining variants all occur within in the same catalytic domain
                (figure 2B). Additional deleterious mutations associated with more severe,
                early-onset clinical phenotypes might exist. However, we did not identify any cases
                in our mtDNA depletion cohort. Furthermore, it is possible that very detrimental
                mutations are embryonic lethal as is seen in knockout mice which are completely
                deficient in RNase H1. Finally, sensory ataxic neuropathy, previously unreported
                with RNASEH1 mutations, expands the recognized clinical phenotype to include ataxia
                neuropathy spectrum, most commonly associated with recessive POLG mutations.</text>
        </passage>
        <passage>
            <infon key="section_type">DISCUSS</infon>
            <infon key="type">paragraph</infon>
            <offset>16163</offset>
            <text>IBD analysis confirmed that families A and B were distantly related. However,
                their haplotype differed from 2 previously reported European pedigrees. These data
                suggest that the c.424G>A p.Val142Ile mutation has arisen independently in the
                lineages analyzed. European admixing of the London-Oxford Indian families harboring
                c.424G>A p.Val142Ile could account for the lack of RNASEH1 mutations in the 50
                additional Indian probands screened. Furthermore, the close proximity of all 3
                families to the CEU (European) HapMap project populations (figure 2A) suggests that
                they belong to the Ancestral North Indian gene pool, which shares up to 70% genetic
                affinities with Europeans.</text>
        </passage>
        <passage>
            <infon key="section_type">DISCUSS</infon>
            <infon key="type">paragraph</infon>
            <offset>16840</offset>
            <text>Our data confirm that RNASEH1 mutations are an important cause of mitochondrial
                disease resulting from the secondary accumulation of multiple mtDNA deletions and
                that the phenotypic spectrum in adults is relatively benign. Nevertheless, RNASEH1
                genetic analysis should be considered in all patients presenting with ataxia
                neuropathy spectrum once POLG mutations have been excluded. Finally, although the
                commonly occurring c.424G>A p.Val142Ile RNASEH1 variant could indicate a mutation
                hotspot within the gene, it might instead reflect an inability of the mutant enzyme
                to bind with a partner protein, thereby allowing Val142Ile RNase H1 to attack its
                substrates indiscriminately. As such, loss-of-function mutations could confer
                different clinical phenotypes.</text>
        </passage>
        <passage>
            <infon key="section_type">SUPPL</infon>
            <infon key="type">title_1</infon>
            <offset>17601</offset>
            <text>Supplementary Material</text>
        </passage>
        <passage>
            <infon key="section_type">SUPPL</infon>
            <infon key="type">footnote</infon>
            <offset>17624</offset>
            <text>Supplemental data at Neurology.org/ng</text>
        </passage>
        <passage>
            <infon key="section_type">AUTH_CONT</infon>
            <infon key="type">title_1</infon>
            <offset>17662</offset>
            <text>AUTHOR CONTRIBUTIONS</text>
        </passage>
        <passage>
            <infon key="section_type">AUTH_CONT</infon>
            <infon key="type">paragraph</infon>
            <offset>17683</offset>
            <text>Enrico Bugiardini: study design, analysis and interpretation of data, and drafting
                the manuscript. Olivia V. Poole: analysis and interpretation of data and revising
                the manuscript. Andreea Manole: acquisition, analysis and interpretation of data,
                and revising the manuscript. Alan M. Pittman, Alejandro Horga, Iain Hargreaves,
                Cathy E. Woodward, Mary G. Sweeney, Janice L. Holton, Jan-Willem Taanman, and Gordon
                T. Plant: acquisition, analysis and interpretation of data, and revising the
                manuscript. Joanna Poulton: study concept, acquisition of data, and revising the
                manuscript. Massimo Zeviani, Daniele Ghezzi, John Taylor, and Conrad Smith:
                acquisition and interpretation of data and revising the manuscript. Carl Fratter:
                study design, acquisition and interpretation of data, and revising the manuscript.
                Meena A. Kanikannan and Arumugam Paramasivam: acquisition and interpretation of data
                and revising the manuscript. Kumarasamy Thangaraj: study concept, acquisition and
                interpretation of data, and revising the manuscript. Antonella Spinazzola, Ian J.
                Holt, and Henry Houlden: study concept and revising the manuscript. Michael G.
                Hanna: study concept, interpretation of data, and revising the manuscript. Robert
                D.S. Pitceathly: study design, analysis and interpretation of data, and drafting the
                manuscript.</text>
        </passage>
        <passage>
            <infon key="section_type">ACK_FUND</infon>
            <infon key="type">title_1</infon>
            <offset>19001</offset>
            <text>STUDY FUNDING</text>
        </passage>
        <passage>
            <infon key="section_type">ACK_FUND</infon>
            <infon key="type">paragraph</infon>
            <offset>19015</offset>
            <text>The research leading to these results has received funding from the European
                Community\'s Seventh Framework Programme (FP7/2007-2013) under grant agreement no.
                2012-305121 "Integrated European:omics research project for diagnosis and therapy in
                rare neuromuscular and neurodegenerative diseases (NEUROMICS)." This work is also
                supported by a Medical Research Council Centre grant (G0601943) and Wellcome Trust
                grant on Synaptopathies. Part of this work was undertaken in the University College
                London Hospitals/University College London Institute of Neurology sequencing
                facility, which received a proportion of funding from the Department of Health\'s
                National Institute for Health Research Biomedical Research Centres funding scheme.
                R.D.S.P. is funded by the National Institute for Health Research. O.V.P. has
                received funding from the Lily Foundation. J.P. receives support from the Lily
                Foundation, NewLife (SG/14-15/11), the Medical Research Council (MR/J010448/1), and
                the Wellcome Trust (0948685/Z/10/Z). K.T. is supported by the Department of
                Biotechnology and the Council of Scientific and Industrial Research
                (BioAge:BSC0118), Government of India. A.P. is supported by the Science and
                Engineering Research Board (PDF/2016/000881), Government of India. A.S. is supported
                by the Medical Research Council Senior Non-Clinical Fellowship, MC_PC_13029.</text>
        </passage>
        <passage>
            <infon key="section_type">COMP_INT</infon>
            <infon key="type">title_1</infon>
            <offset>20377</offset>
            <text>DISCLOSURE</text>
        </passage>
        <passage>
            <infon key="section_type">COMP_INT</infon>
            <infon key="type">paragraph</infon>
            <offset>20388</offset>
            <text>Enrico Bugiardini, Olivia V. Poole, Andreea Manole, Alan M. Pittman, Alejandro
                Horga, Iain Hargreaves, Cathy E. Woodward, and Mary G. Sweeney report no
                disclosures. Janice L. Holton has received travel funding from Merck-Serono; has
                served on the editorial board of Neuropathology and Applied Neurobiology; has been
                an employee of University College London; and has received research support from
                Alzheimer\'s Research Trust, The Margaret Watson Memorial Trust Grant from The Sarah
                Matheson Trust, Action Medical Research, Brain Net Europe: Support for the Queen
                Square Brain Bank for Neurological Disorders, The Sarah Matheson Trust, Myositis
                Support Group, The Multiple System Atrophy Trust, the Michael J Fox Foundation for
                Parkinson\'s Research, Alzheimer\'s Research UK, MSA Coalition, and the King
                Baudouin Foundation Sophia Fund. Jan-Willem Taanman has served on the scientific
                advisory board of Novintum Bioscience Ltd.; has received research support from Royal
                Free Charity; and receives royalty payments from the University of Oregon. Gordon T.
                Plant has served on the editorial board of Neuro-Ophthalmology. Joanna Poulton and
                Massimo Zeviani report no disclosures. Daniele Ghezzi has served on the editorial
                board of Orphanet Journal of Rare Diseases and has received research support from
                the Italian Ministry of Health, European Communities, Foundation Telethon, CARIPLO
                Foundation Italy, and the Pierfranco and Luisa Mariani Foundation of Italy. John
                Taylor, Conrad Smith, Carl Fratter, and Meena A. Kanikannan report no disclosures.
                Arumugam Paramasivam has received research support from DST-SERB National Post
                Doctoral Fellowship No.: PDF/2016/000881. Kumarasamy Thangaraj has served on the
                editorial boards of Mitochondrion, PLoS One, BMC Medical Genetics, Scientific
                Reports, and Clinical Genetics. Antonella Spinazzola reports no disclosures. Ian J.
                Holt has received research support from Medical Research Council UK. Henry Houlden
                has received research support from The Medical Research Council (MRC) UK, The BRT,
                The MDA USA, Muscular Dystrophy UK, Ataxia UK, Muscular Dystrophy UK, Rosetrees
                Trust, The Wellcome Trust, and the National Institute for Health (NIHR). Michael G.
                Hanna has been a consultant for Novartis and has received research support from an
                MRC Centre Grant and the Myositis Support Group. Robert D.S. Pitceathly reports no
                disclosures. Go to Neurology.org/ng for full disclosure forms.</text>
        </passage>
        <passage>
            <infon key="section_type">ABBR</infon>
            <infon key="type">title</infon>
            <offset>22815</offset>
            <text>GLOSSARY</text>
        </passage>
        <passage>
            <infon key="section_type">ABBR</infon>
            <infon key="type">paragraph</infon>
            <offset>22824</offset>
            <text>COX</text>
        </passage>
        <passage>
            <infon key="section_type">ABBR</infon>
            <infon key="type">paragraph</infon>
            <offset>22828</offset>
            <text>cytochrome c oxidase</text>
        </passage>
        <passage>
            <infon key="section_type">ABBR</infon>
            <infon key="type">paragraph</infon>
            <offset>22849</offset>
            <text>IBD</text>
        </passage>
        <passage>
            <infon key="section_type">ABBR</infon>
            <infon key="type">paragraph</infon>
            <offset>22853</offset>
            <text>identity by descent</text>
        </passage>
        <passage>
            <infon key="section_type">ABBR</infon>
            <infon key="type">paragraph</infon>
            <offset>22873</offset>
            <text>mtDNA</text>
        </passage>
        <passage>
            <infon key="section_type">ABBR</infon>
            <infon key="type">paragraph</infon>
            <offset>22879</offset>
            <text>mitochondrial DNA</text>
        </passage>
        <passage>
            <infon key="section_type">ABBR</infon>
            <infon key="type">paragraph</infon>
            <offset>22897</offset>
            <text>NCS</text>
        </passage>
        <passage>
            <infon key="section_type">ABBR</infon>
            <infon key="type">paragraph</infon>
            <offset>22901</offset>
            <text>nerve conduction studies</text>
        </passage>
        <passage>
            <infon key="section_type">ABBR</infon>
            <infon key="type">paragraph</infon>
            <offset>22926</offset>
            <text>PCA</text>
        </passage>
        <passage>
            <infon key="section_type">ABBR</infon>
            <infon key="type">paragraph</infon>
            <offset>22930</offset>
            <text>principal component analysis</text>
        </passage>
        <passage>
            <infon key="section_type">ABBR</infon>
            <infon key="type">paragraph</infon>
            <offset>22959</offset>
            <text>PEO</text>
        </passage>
        <passage>
            <infon key="section_type">ABBR</infon>
            <infon key="type">paragraph</infon>
            <offset>22963</offset>
            <text>progressive external ophthalmoplegia</text>
        </passage>
        <passage>
            <infon key="section_type">ABBR</infon>
            <infon key="type">paragraph</infon>
            <offset>23000</offset>
            <text>RNase H1</text>
        </passage>
        <passage>
            <infon key="section_type">ABBR</infon>
            <infon key="type">paragraph</infon>
            <offset>23009</offset>
            <text>ribonuclease H1</text>
        </passage>
        <passage>
            <infon key="section_type">ABBR</infon>
            <infon key="type">paragraph</infon>
            <offset>23025</offset>
            <text>RRF</text>
        </passage>
        <passage>
            <infon key="section_type">ABBR</infon>
            <infon key="type">paragraph</infon>
            <offset>23029</offset>
            <text>ragged red fiber</text>
        </passage>
        <passage>
            <infon key="section_type">REF</infon>
            <infon key="type">title</infon>
            <offset>23046</offset>
            <text>REFERENCES</text>
        </passage>
        <passage>
            <infon key="fpage">429</infon>
            <infon key="lpage">444</infon>
            <infon key="name_0">surname:DiMauro;given-names:S</infon>
            <infon key="name_1">surname:Schon;given-names:EA</infon>
            <infon key="name_2">surname:Carelli;given-names:V</infon>
            <infon key="name_3">surname:Hirano;given-names:M</infon>
            <infon key="pub-id_pmid">23835535</infon>
            <infon key="section_type">REF</infon>
            <infon key="source">Nat Rev Neurol</infon>
            <infon key="type">ref</infon>
            <infon key="volume">9</infon>
            <infon key="year">2013</infon>
            <offset>23057</offset>
            <text>The clinical maze of mitochondrial neurology</text>
        </passage>
        <passage>
            <infon key="fpage">186</infon>
            <infon key="lpage">193</infon>
            <infon key="name_0">surname:Reyes;given-names:A</infon>
            <infon key="name_1">surname:Melchionda;given-names:L</infon>
            <infon key="name_2">surname:Nasca;given-names:A</infon>
            <infon key="pub-id_pmid">26094573</infon>
            <infon key="section_type">REF</infon>
            <infon key="source">Am J Hum Genet</infon>
            <infon key="type">ref</infon>
            <infon key="volume">97</infon>
            <infon key="year">2015</infon>
            <offset>23102</offset>
            <text>RNASEH1 mutations impair mtDNA replication and cause adult-onset mitochondrial
                encephalomyopathy</text>
        </passage>
        <passage>
            <infon key="fpage">3360</infon>
            <infon key="lpage">3364</infon>
            <infon key="name_0">surname:Keller;given-names:W</infon>
            <infon key="name_1">surname:Crouch;given-names:R</infon>
            <infon key="pub-id_pmid">4343966</infon>
            <infon key="section_type">REF</infon>
            <infon key="source">Proc Natl Acad Sci USA</infon>
            <infon key="type">ref</infon>
            <infon key="volume">69</infon>
            <infon key="year">1972</infon>
            <offset>23199</offset>
            <text>Degradation of DNA RNA hybrids by ribonuclease H and DNA polymerases of cellular
                and viral origin</text>
        </passage>
        <passage>
            <infon key="fpage">807</infon>
            <infon key="lpage">815</infon>
            <infon key="name_0">surname:Cerritelli;given-names:SM</infon>
            <infon key="name_1">surname:Frolova;given-names:EG</infon>
            <infon key="name_2">surname:Feng;given-names:C</infon>
            <infon key="name_3">surname:Grinberg;given-names:A</infon>
            <infon key="name_4">surname:Love;given-names:PE</infon>
            <infon key="name_5">surname:Crouch;given-names:RJ</infon>
            <infon key="pub-id_pmid">12667461</infon>
            <infon key="section_type">REF</infon>
            <infon key="source">Mol Cell</infon>
            <infon key="type">ref</infon>
            <infon key="volume">11</infon>
            <infon key="year">2003</infon>
            <offset>23297</offset>
            <text>Failure to produce mitochondrial DNA results in embryonic lethality in Rnaseh1
                null mice</text>
        </passage>
        <passage>
            <infon key="fpage">9334</infon>
            <infon key="lpage">9339</infon>
            <infon key="name_0">surname:Holmes;given-names:JB</infon>
            <infon key="name_1">surname:Akman;given-names:G</infon>
            <infon key="name_2">surname:Wood;given-names:SR</infon>
            <infon key="pub-id_pmid">26162680</infon>
            <infon key="section_type">REF</infon>
            <infon key="source">Proc Natl Acad Sci USA</infon>
            <infon key="type">ref</infon>
            <infon key="volume">112</infon>
            <infon key="year">2015</infon>
            <offset>23386</offset>
            <text>Primer retention owing to the absence of RNase H1 is catastrophic for
                mitochondrial DNA replication</text>
        </passage>
        <passage>
            <infon key="fpage">E4276</infon>
            <infon key="lpage">E4285</infon>
            <infon key="name_0">surname:Akman;given-names:G</infon>
            <infon key="name_1">surname:Desai;given-names:R</infon>
            <infon key="name_2">surname:Bailey;given-names:LJ</infon>
            <infon key="pub-id_pmid">27402764</infon>
            <infon key="section_type">REF</infon>
            <infon key="source">Proc Natl Acad Sci USA</infon>
            <infon key="type">ref</infon>
            <infon key="volume">113</infon>
            <infon key="year">2016</infon>
            <offset>23486</offset>
            <text>Pathological ribonuclease H1 causes R-loop depletion and aberrant DNA segregation
                in mitochondria</text>
        </passage>
        <passage>
            <infon key="fpage">1762</infon>
            <infon key="lpage">1770</infon>
            <infon key="name_0">surname:Lieber;given-names:DS</infon>
            <infon key="name_1">surname:Calvo;given-names:SE</infon>
            <infon key="name_2">surname:Shanahan;given-names:K</infon>
            <infon key="pub-id_pmid">23596069</infon>
            <infon key="section_type">REF</infon>
            <infon key="source">Neurology</infon>
            <infon key="type">ref</infon>
            <infon key="volume">80</infon>
            <infon key="year">2013</infon>
            <offset>23584</offset>
            <text>Targeted exome sequencing of suspected mitochondrial disorders</text>
        </passage>
        <passage>
            <infon key="fpage">285</infon>
            <infon key="lpage">291</infon>
            <infon key="name_0">surname:Lek;given-names:M</infon>
            <infon key="name_1">surname:Karczewski;given-names:KJ</infon>
            <infon key="name_2">surname:Minikel;given-names:EV</infon>
            <infon key="pub-id_pmid">27535533</infon>
            <infon key="section_type">REF</infon>
            <infon key="source">Nature</infon>
            <infon key="type">ref</infon>
            <infon key="volume">536</infon>
            <infon key="year">2016</infon>
            <offset>23647</offset>
            <text>Analysis of protein-coding genetic variation in 60,706 humans</text>
        </passage>
        <passage>
            <infon key="fpage">62</infon>
            <infon key="lpage">71</infon>
            <infon key="name_0">surname:Lax;given-names:NZ</infon>
            <infon key="name_1">surname:Whittaker;given-names:RG</infon>
            <infon key="name_2">surname:Hepplewhite;given-names:PD</infon>
            <infon key="pub-id_pmid">22189570</infon>
            <infon key="section_type">REF</infon>
            <infon key="source">Brain</infon>
            <infon key="type">ref</infon>
            <infon key="volume">135</infon>
            <infon key="year">2012</infon>
            <offset>23709</offset>
            <text>Sensory neuronopathy in patients harbouring recessive polymerase gamma mutations</text>
        </passage>
        <passage>
            <infon key="fpage">731</infon>
            <infon key="lpage">744</infon>
            <infon key="name_0">surname:Metspalu;given-names:M</infon>
            <infon key="name_1">surname:Romero;given-names:IG</infon>
            <infon key="name_2">surname:Yunusbayev;given-names:B</infon>
            <infon key="pub-id_pmid">22152676</infon>
            <infon key="section_type">REF</infon>
            <infon key="source">Am J Hum Genet</infon>
            <infon key="type">ref</infon>
            <infon key="volume">89</infon>
            <infon key="year">2011</infon>
            <offset>23790</offset>
            <text>Shared and unique components of human population structure and genome-wide signals
                of positive selection in South Asia</text>
        </passage>
    </document>
</collection>